acquired
Stage
About
Landos Biopharma develops NX-13, an oral NLRX1 agonist in Phase 2 clinical trials, targeting inflammatory bowel diseases such as ulcerative colitis and Crohn's disease by regulating immunometabolism and inflammation.
Explore Landos Biopharma's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.